PE20180195A1 - Usos farmaceuticos novedosos - Google Patents

Usos farmaceuticos novedosos

Info

Publication number
PE20180195A1
PE20180195A1 PE2017001509A PE2017001509A PE20180195A1 PE 20180195 A1 PE20180195 A1 PE 20180195A1 PE 2017001509 A PE2017001509 A PE 2017001509A PE 2017001509 A PE2017001509 A PE 2017001509A PE 20180195 A1 PE20180195 A1 PE 20180195A1
Authority
PE
Peru
Prior art keywords
novel pharmaceutical
cab
pharmaceutical uses
vonoprazan
revaprazan
Prior art date
Application number
PE2017001509A
Other languages
English (en)
Inventor
Richard Jenkins
Mark Hibberd
Original Assignee
Takeda Pharmaceuticals Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=55806738&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20180195(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GBGB1505526.2A external-priority patent/GB201505526D0/en
Priority claimed from GBGB1521015.6A external-priority patent/GB201521015D0/en
Application filed by Takeda Pharmaceuticals Co filed Critical Takeda Pharmaceuticals Co
Publication of PE20180195A1 publication Critical patent/PE20180195A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Abstract

La invencion proporciona un bloqueador de acido competitivo con potasio (P-CAB) para usarse en el tratamiento, prevencion y/o reduccion de sintomas de la enfermedad por reflujo gastroesofagico (ERGE) en pacientes que responden de manera parcial a un inbibidor de la bomba de protones (IBP). El P-CAB puede, por ejemplo, seleccionarse de 1-[5-(2-fluorofenil)-1- (piridin-3-ilsulfonil)-1 H-pirrol-3-il]-N-metilmetanamina (vonoprazan), revaprazan (YH1855), YH4808, RQ-4 y CS-526, o una sal de los mismos
PE2017001509A 2015-03-31 2016-03-30 Usos farmaceuticos novedosos PE20180195A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB1505526.2A GB201505526D0 (en) 2015-03-31 2015-03-31 Novel pharmaceutical uses
GBGB1521015.6A GB201521015D0 (en) 2015-11-27 2015-11-27 Novel pharmaceutical uses

Publications (1)

Publication Number Publication Date
PE20180195A1 true PE20180195A1 (es) 2018-01-26

Family

ID=55806738

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2017001509A PE20180195A1 (es) 2015-03-31 2016-03-30 Usos farmaceuticos novedosos

Country Status (22)

Country Link
US (2) US20180085361A1 (es)
EP (1) EP3277279A1 (es)
JP (1) JP2018513140A (es)
KR (1) KR20170132260A (es)
CN (1) CN107530335A (es)
AU (1) AU2016241069A1 (es)
BR (1) BR112017021024A2 (es)
CA (1) CA2981244A1 (es)
CL (1) CL2017002325A1 (es)
CO (1) CO2017010019A2 (es)
CR (1) CR20170404A (es)
DO (1) DOP2017000218A (es)
EA (1) EA201792148A1 (es)
EC (1) ECSP17072984A (es)
IL (1) IL254419A0 (es)
MA (1) MA41850A (es)
MX (1) MX2017012414A (es)
PE (1) PE20180195A1 (es)
PH (1) PH12017501751A1 (es)
SG (1) SG11201706739WA (es)
TN (1) TN2017000416A1 (es)
WO (1) WO2016159386A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2980109A1 (en) 2015-03-31 2016-10-06 Mutabilis Heterocyclic compounds and their use in preventing or treating bacterial infections
WO2019013310A1 (en) 2017-07-10 2019-01-17 Takeda Pharmaceutical Company Limited PREPARATION COMPRISING VONOPRAZAN
WO2024027549A1 (zh) * 2022-08-04 2024-02-08 江苏柯菲平医药股份有限公司 一种含有吡咯类胃酸分泌抑制剂的药物组合物及其制备方法
CN116270443A (zh) * 2022-10-27 2023-06-23 广州白云山天心制药股份有限公司 富马酸伏诺拉生注射液及其制备方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7662832B2 (en) 2004-09-03 2010-02-16 Yuhan Corporation Pyrrolo[2,3-c]pyridine derivatives and processes for the preparation thereof
US20080255200A1 (en) * 2007-04-11 2008-10-16 Auspex Pharmaceuticals, Inc. Substituted benzimidazoles
BRPI0916689A2 (pt) 2008-07-28 2015-11-17 Takeda Pharmaceutical composição farmacêutica estabilizada, preparação sólida, e, métodos para estabilizar uma composição farmacêutica, e para estabilizar uma preparação sólida.
WO2011004882A1 (ja) 2009-07-09 2011-01-13 ラクオリア創薬株式会社 消化管運動異常が関与する疾患を治療するためのアシッドポンプ拮抗剤
CA2902624C (en) 2013-02-28 2021-05-18 Takeda Pharmaceutical Company Limited Method for producing sulfonyl chloride compound
CN103951652B (zh) * 2014-04-18 2015-09-23 潍坊博创国际生物医药研究院 5-(2-氟苯基)-n-甲基-1-(3-吡啶基磺酰基)-1h-吡咯-3-甲胺水溶性有机酸盐和注射剂及它们的制备方法

Also Published As

Publication number Publication date
CA2981244A1 (en) 2016-10-06
PH12017501751A1 (en) 2018-04-11
CR20170404A (es) 2018-01-10
CN107530335A (zh) 2018-01-02
TN2017000416A1 (en) 2019-01-16
EP3277279A1 (en) 2018-02-07
MX2017012414A (es) 2018-01-26
WO2016159386A1 (en) 2016-10-06
CO2017010019A2 (es) 2018-02-20
US20180085361A1 (en) 2018-03-29
US20190070159A1 (en) 2019-03-07
BR112017021024A2 (pt) 2018-07-03
DOP2017000218A (es) 2018-01-31
MA41850A (fr) 2018-02-06
SG11201706739WA (en) 2017-09-28
CL2017002325A1 (es) 2017-12-29
IL254419A0 (en) 2017-11-30
EA201792148A1 (ru) 2018-02-28
ECSP17072984A (es) 2018-02-28
AU2016241069A1 (en) 2017-09-21
JP2018513140A (ja) 2018-05-24
KR20170132260A (ko) 2017-12-01

Similar Documents

Publication Publication Date Title
ECSP17072984A (es) Procesos farmacéuticos novedosos
AR090269A1 (es) Composicion farmaceutica y sus usos
EA201300987A1 (ru) Фармацевтические композиции, включающие метформин и ингибитор dpp-4 или ингибитор sglt-2
CO6382116A2 (es) Composiciones que comprenden un arilpirazol y/o una formamidina, métodos y usos de las mismas
EA201590358A1 (ru) Ингибиторы репликации вируса иммунодефицита человека
CL2011000806A1 (es) Uso de etexilato de dabigatran o una sal del mismo para preparar un medicamento util para la prevencion del ictus en pacientes que padecen fibrilacion auricular.
CO2017008115A2 (es) Ácido (2s,4r)-5-(5'-cloro-2'-fluorobifenil-4-il)-4-(etoxioxalilamino)-2-hidroximetil-2-metilpentanoico
PE20170469A1 (es) Metodos para mejorar el rendimiento miocardico en pacientes con cirugia de fontano que utilizan composiciones de udenafilo
MX2018008614A (es) Inhibidores de il-8 para usarse en el tratamiento de neuropatia periferica inducida por quimioterapia.
CL2017000578A1 (es) Tratamiento del cáncer con el inhibidor de la alfa-amilasa en los animales de compañia
CL2011000805A1 (es) Uso de etexilato de dabigatran o una sal del mismo para preparar un medicamento util para la prevencion de lictus en pacientes que padecen fibrilacion auricular.
CL2018002539A1 (es) Ácido (2s,4r)-5-(5'-cloro-2'-fluoro-[1,1'-bifenil]-4-il)-2-(etoximetil)-4-(3-hidroxiisoxazol-5-carboxamido)-2-metilpentanoico cristalino, y sus usos
EA201990947A1 (ru) Замещенные производные 6-(1h-пиразол-1-ил)пиримидин-4-амина и их применение
CO2018002046A2 (es) Nueva composición oral de libreación retardada dual de dexlansoprazol
AR103219A1 (es) Compuesto de (1h-indol-3-il)propan-1-ona, composición farmacéutica, combinación y mezcla que lo comprenden y su uso para la fabricación de un medicamento
CO2017011264A2 (es) El compuesto 1-(2-aminoetil)-6-(2-(2-hidroxietoxi)-5-metilfenil)-2-tioxo-2,3-dihidropirimidin-4(1h)-ona, sales, composiciones que lo comprenden y procedimientos de elaboración del mismo
MA44513B1 (fr) Formulations injectables de fosnetupitant physiologiquement equilibrees
FR3056908B1 (fr) Sel de metformine et d'elafibranor presentant une activite duale pour le traitement de l'obesite associee a la steato-hepatite non alcoolique (nash) et a l'hypertriglyceridemie
EA202090165A1 (ru) Фармацевтическая композиция для предупреждения или лечения сердечно-сосудистых заболеваний, сопровождающихся диабетом, содержащая амлодипин, лозартан и розувастатин, и комбинированный препарат, содержащий ее
BR112018001836A2 (pt) preparação contendo octocrileno estável ao odor
CO2019005207A2 (es) Complejo medicinal para tratar diabetes tipo 2 y dislipidemia diabética
CR20160177A (es) Formas de dosificación farmacéutica que comprenden 1-[6-(morfolin-4-il) pirimidin-4-il]-4-(1h-1,2,3-triazol-1-il)1h-pirazol-5-olato de sodio
UA117330C2 (uk) Склад лікарського препарату протигрибкової, протимікробної та кератолітичної дії
TH166468B (th) รูปแบบเภสัชภัณฑ์ซึ่งประกอบรวมด้วยโซเดียม 1-[6-(มอร์โฟลิน-4-อิล)ไพริมิดิน-4- อิล]-4-(1h-1,2,3-ไตรอะโซล-1-อิล)-1h-ไพราโซล-5-โอเลต
TH166468A (th) รูปแบบเภสัชภัณฑ์ซึ่งประกอบรวมด้วยโซเดียม 1-[6-(มอร์โฟลิน-4-อิล)ไพริมิดิน-4- อิล]-4-(1h-1,2,3-ไตรอะโซล-1-อิล)-1h-ไพราโซล-5-โอเลต